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AbstrAct
Objectives To compare susceptibility of five different 
stent platforms with longitudinal stent deformation (LSD) 
using a clinically relevant bench testing model simulating 
both short and long malapposed lengths.
Background Recent data suggest that design 
modifications to the Promus Element stent which led to 
the Promus Premier stent has reduced susceptibility to 
LSD. However, susceptibility to LSD at long malapposed 
lengths has not been tested. Furthermore, the mechanisms 
behind susceptibility to LSD are as yet unclear.
Methods The Omega, Integrity, Multilink 8, Biomatrixand 
Promus Premier stent platforms were tested. The Omega, 
Integrity and Multilink 8 platforms were used in place 
of their drug-eluting equivalents. 3.5 mm stents were 
deployed in a stepped tube with the distal portion fixed 
and the proximal test section exposed. The force required 
to compress stents by a fixed distance at different exposed 
lengths was compared. Symmetrical and point loading 
were used.
Results The Promus Premier was longitudinally as strong 
as Multilink and Integrity at a short exposed length (4 mm) 
but weaker, in between Omega and the other platforms, 
at longer exposed lengths (12 mm). As previously noted, 
the Omega (Promus Element) platform was significantly 
weaker than the other stents and Biomatrix was the 
strongest stent.
Conclusion Susceptibility to LSD varies depending on 
length of malapposed segment when tested using a 
clinically relevant model as in this study. The mechanisms 
behind the susceptibility are likely multifactorial, including 
connector number, strut thickness, connector alignment 
and ring orientation but remain to be elucidated. 
IntROduCtIOn
A major focus over recent years has been to 
improve stent deliverability and conform-
ability, using a number of modifications to 
the stent design, including changes to the 
stent platform itself. While increasing deliv-
erability and conformability, such design 
changes may have unexpected outcomes, 
with susceptibility to longitudinal stent defor-
mation (LSD) being one of them, due to 
reduced longitudinal strength.1 2 This infre-
quently reported complication is usually a 
result of a compressive force localised to 
one or two contact points on the proximal 
circumference of a malapposed stent.2 3 LSD 
of the Promus Element stent (Boston Scien-
tific, Natick, Massachusetts, USA) has been 
reported in both bench testing and clinical 
studies.4–6 Results from bench testing models 
showed that the Promus Element required 
significantly less force to compress than other 
contemporary stent platforms. This led to 
modification of the Promus Element stent by 
adding extra connectors between the prox-
imal three rings in the Promus Premier stent, 
while retaining the same ring and connector 
structure in the rest of the stent, to reduce 
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Key questions
What is already known about this subject?
 ► Susceptibility to longitudinal stent deformation 
(LSD) varies greatly depending on stent design. 
However, the factors related to LSD susceptibility 
are poorly understood. Current bench testing 
models have limited clinical relevance due to either 
limited range of test conditions or unrepresentative 
modelling. More extensive modelling is therefore 
required.
What does this study add?
 ► The Promus Premier stent was significantly more 
susceptible to LSD at longer exposure lengths. In 
addition to connector number, LSD susceptibility 
is likely affected by ring-to-ring orientation, strut 
thickness and connector alignment. However, this 
study is only hypothesis generating and further 
work is needed to elucidate the mechanisms 
responsible for LSD susceptibility.
How might this impact on clinical practice?
 ► The Promus Premier stent is likely to be particularly 
prone to LSD at longer malapposition lengths. 
Platforms that share design features with the 
Promus Element and Premier stents are also likely 
to be prone to LSD. The multiple factors that affect 
susceptibility to LSD need to be considered in 
current and future stent designs.
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Table 1 Stent platform characteristics
Omega Integrity Multilink 8 Biomatrix Promus premier
Strut thickness (µM) 81 91 81 112 81
Phase In Out In Out In
Connector number 2 2 and 3 3 3 4 (proximal three hoops); 
two for rest
Connector alignment/shape Non-aligned Welds Aligned; u-bend S-shaped Non-aligned
Figure 1 Compression testing. Diagram showing 
symmetrical compression with a rod (A), point testing with a 
fork mid-connector (B) or over connector (C).
susceptibility to LSD. However, previous bench models 
have been very limited in their scope, with models that 
lack clinical relevance or focus only on connector number 
or orientation.
Previous bench testing studies have predominantly used 
symmetrical compression testing of stents, that is, applied 
uniform force over the entire circumference of the 
stent, supported from the inside by a mandril. Recently, 
Ormiston et al have used a more clinically relevant bench 
testing model of LSD.7 Using this model, they tested the 
newer Promus Premier stent against other platforms 
including the Promus Element and reported a signifi-
cantly improved longitudinal strength in the Promus 
Premier stent. However, there have been clinical case 
reports of LSD with the Promus Premier stent.8 In Ormis-
ton’s second paper, they tested the reinforced proximal 
end of the Promus Premier stent; however, it is uncertain 
whether under different conditions, for example, longer 
exposed lengths, the platform would behave differently.7 
Furthermore, it is important to characterise the mecha-
nisms leading to LSD, which are as yet unclear, as this will 
be important in future stent design. In our study, we used 
a similar model to Ormiston. However, in contrast to the 
Ormiston study that used a 5 mm exposure length (ie, 
the length of stent mimicking the malapposition length), 
we used three clinically relevant exposure lengths: 4, 7m 
and 12 mm. The longer exposure length is particularly 
relevant in clinical scenarios such as bifurcation stenting 
or with a long stent in a tapered vessel prior to postdila-
tion. We looked at the differences between platforms and 
specifically how the Promus Premier and Element stents 
compare with other commonly used platforms at the time 
of this study, particularly at the longer exposure lengths 
which has as yet not been reported.
MetHOds
stent platforms
We compared five platforms: Omega (Boston Scientific), 
Multilink 8 (Abbott Vascular, Redwood City, California, 
USA), Integrity (Medtronic, Minneapolis, USA), Bioma-
trix Flex (Biosensors, Singapore) and Promus Premier 
(Boston Scientific). The former three bare metal stents 
were chosen as they are the identical platforms to the 
drug-eluting Promus and Taxus Element (Boston Scien-
tific), Xience Prime (Abbott Vascular,) and Resolute 
Integrity (Medtronic) stents, respectively. The Biomatrix 
Flex and Promus Premier stents do not have bare metal 
equivalents. We chose 3.5 mm diameter stents for all plat-
forms to avoid testing a mixture of small and large vessel 
platforms that exist for 3 mm diameter stents depending 
on the manufacturer. Stent length was greater than 
18 mm in all cases. Table 1 shows the stent platform struc-
tures and characteristics for the stents used.
Coronary artery model
Stents were deployed in a coronary artery model in which 
the stent was embedded into vessel wall in the distal 
section, and unapposed in the proximal test section. 
The coronary artery model for point testing consisted of 
a rigid transparent acrylic tube (inner diameter 5 mm) 
with a soft silicone tube (inner diameter 3 mm) placed 
within its distal half creating a lumen with a step in diam-
eter from 3 to 5 mm. The model used for symmetrical 
testing used larger tubes with a step in diameter from 3 
to 7 mm to allow free movement of the rod delivering the 
compression. The gap between the stent and the outer 
tube was 0.75 mm in our coronary model. The stent was 
deployed at nominal pressure across this step resulting 
in its distal portion being embedded in the silicone 
tubing and its proximal portion completely unapposed 
above the step. Compression was therefore limited to the 
exposed section.
Compression testing protocol
We performed symmetrical and point compression of 
different exposed lengths of stent and compared the 
forces required to produce shortening equivalent with 
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that observed in clinical cases of LSD. Three different 
‘exposed lengths’ of stent were used (4, 7 and 12 mm) 
to replicate a range of possible clinical scenarios. A 4 mm 
diameter rod was used to deliver symmetrical compres-
sion to the whole proximal end of the stent. A forked 
pin was used to deliver point compression (figure 1). 
The first series of point and symmetric testing were 
done at 7 mm exposed length. Five repetitions for each 
stent were performed at each position, compressing 
each stent by 4 mm (as this was the first series of tests, an 
additional ≤1 mm compression was carried out to ensure 
that the required 4 mm compression was obtained). 
The force necessary for each millimetre compression 
was recorded.
The next series of point and symmetrical compression 
testing were performed at 4 and 12 mm exposed lengths, 
which were compressed 2.5 and 7 mm, respectively. The 
force required to compress the platform was measured at 
0.5 and 1 mm compression intervals, respectively.
Four repetitions of point and symmetrical compres-
sions were performed. Five repetitions (similar to the 
7 mm exposure) could not be performed due to logistical 
reasons with stent platform availability.
Photographic images
Static images were obtained of the compressed stent plat-
forms using a Nikkon digital camera.
statistical analysis
For point testing, we first compared over connector and 
mid-connector compression for each platform. Following 
this analysis, if no significant difference was to be noted 
between over connector and mid-connector values, the 
values were pooled as ‘point loading’ at each exposed 
length. Platforms were then compared under symmetrical 
loading and point loading respectively by comparing the 
force required to compress each platform up to 2.5 mm 
for 4 mm exposed length, up to 4 mm for 7 mm exposed 
length and up to 7 mm at 12 mm exposed length. Repeti-
tions were averaged by taking an arithmetic mean force, 
and by sixth order polynomial least-squares curve fitting. 
For continuous variables, appropriate parametric (paired 
t test for paired and independent samples t test for 
non-paired data, one-way analysis of variance for multiple 
comparisons with Bonferroni correction) tests were used.
Results
Mid-connector versus over connector and point versus 
symmetrical testing
At 7 mm exposure, no significant difference was 
found in the force required to compress a platform by 
4 mm between mid-connector (0.439±0.030 N) and 
over connector (0.426±0.037 N) point compression 
(p=0.799). Thus, we pooled the mid-connector and over 
connector measurements and labelled this as ‘point 
testing’ for subsequent analysis. Symmetrical loading 
required approximately twice the force as point testing 
to cause 4 mm displacement (0.771±0.080 vs 0.433±0.024; 
p≤0.0001) Force–displacement curves for each stent are 
shown in online supplementary figure S1 .
At 4 mm exposure, no significant difference was found 
between mid-connector and over connector compres-
sion (0.479±0.052 N vs 0.526±0.810; p=0.627). Symmetric 
testing was then compared against point testing and 
found to be approximately twice the force required for 
point testing (1.095±0.108 vs 0.503±0.047 N; p<0.0001).
At 12 mm exposure, no significant difference was found 
between mid-connector and over connector compression 
(0.594±0.075 N vs 0.542±0.070 N; p=0.620). The force 
required to compress the stent using point testing was 
not significantly lower than that for symmetrical testing 
at 12 mm exposure (0.568±0.050 N vs 0.676±0.050 N; 
p=0.135).
Comparison between stents point and symmetrical testing
Seven-millimetre exposure point testing
The Omega stent was significantly weaker than every 
other stent using point compression (p<0.0001 for each 
comparison). The Biomatrix stent was significantly 
stronger than all other stents (p<0.0001 for each compar-
ison). The Promus Premier was not significantly stronger 
or weaker when compared with the Integrity or Multilink 
8 stents (p=0.187 and p>0.999, respectively)
Seven-millimetre exposure symmetrical testing
The Omega stent was significantly weaker than all other 
stents (vs Integrity p=0.0002; vs Multilink 8 p=0.0001; 
vs Biomatrix p<0.0001; vs Promus Premier p=0.003), 
The Biomatrix stent was significantly stronger than 
all other stents (p<0.0001 for each comparison). The 
Promus Premier was not significantly stronger or weaker 
when compared with the Integrity or Multilink 8 stents 
(p>0.999).
Four-millimetre exposure point testing
The Omega stent was the weakest of all the stents and 
significantly weaker than the Biomatrix and Integrity 
stents (p=0.004 and p=0.037, respectively). None of the 
other comparisons were statistically significant.
Four-millimetre exposure symmetrical testing
The Omega stent was significantly weaker than all other 
stents except the Multilink 8 stent. The Biomatrix stent 
was significantly stronger than the Multilink 8, Integrity 
and the Omega stents but not the Promus Premier stent. 
The Promus Premier stent was not significantly different 
to the Integrity, Multilink 8 and as mentioned previously, 
the Biomatrix stent.
Twelve-millimetre exposure point testing
The Omega stent was significantly weaker than all other 
stents (p<0.0001) except the Promus Premier (p=0.085). 
The Biomatrix stent was the strongest of all the stents 
being significantly stronger than the Promus, Integrity 
and Omega stents. The Promus Premier stent came out 
significantly weaker than the Integrity (p=0.030) and 
Multilink 8 (p<0.0001) stents.
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Figure 2 Panels  A–C shows a 7 mm exposed Biomatrix stent prior to point compression, the first ring-to-ring contact (0.7 mm 
compression) and following 4 mm compression. Panels D–F shows the Integrity stent prior to point compression, the first ring-
to-ring contact (0.5 mm compression) and following 4 mm compression. Panels G–I shows a 7 mm exposed Multilink stent prior 
to point compression, the first ring-to-ring contact (3 mm compression) and following 4 mm compression. Panels J–L shows 
a 7 mm exposed Omega stent prior to point compression, the first ring-to-ring contact (2.5 mm compression) and following 
4 mm compression. Panels M–O shows a 7 mm exposed Premier stent prior to point compression, the first ring-to-ring contact 
(2.5 mm compression) and following 4 mm compression. Arrows indicate the ring-to-ring contacts. The proximal three rings 
of the Premier stent (O) have remained intact with the compression occurring below, and there is less recoil than the other 
platforms. Visual inspection of the inlet angle (α) shows it is steeper for the Biomatrix, Integrity and Multilink stents that the 
Omega and Premier stents.
Twelve-millimetre exposure symmetrical testing
The Omega stent was the weakest of all the stents and was 
significantly weaker than all stents except the Multilink 8 
(p=0.060). Although, numerically Biomatrix appeared the 
strongest stent, there was no significant difference between 
the force required for symmetrical compression between the 
Promus Premier, Multilink, Integrity and Biomatrix stents.
Online supplementary figure S2 shows force displacement 
curves for point and symmetrical loading for each stent at 
all three exposure lengths. Statistical results of individual 
comparisons between stents are shown in online supplemen-
tary tables 1–6.
Photographic images of compressed stents
Figure 2 shows each exposed stent prior to point compres-
sion, the first ring-to-ring contact and following 4 mm 
compression. Compared with the other platforms, the 
proximal three rings of the Premier stent remained intact 
at 4 mm point compression with the compression occur-
ring below and there was less recoil. Visual inspection 
of the inlet angle (α) showed that it was steeper for the 
Biomatrix, Integrity and Multilink stents than the Omega 
and Premier stents. Angles were assessed by visual inspec-
tion only and not measured. Figure 3 shows the Multilink 
8, Biomatrix, Integrity and Omega platforms at different 
phases in the compression testing. The appearances of 
the stents following point loading closely resemble cases 
of LSD. Online supplementary figure S3 shows a compar-
ison between an in-phase (Multilink 8) and out-of-phase 
(Integrity) platforms, showing the various phases of stent 
distortion during the compressive force. In the Integ-
rity stent, during compression, the rings were in contact 
within 0.5 mm. This was followed by slippage, with the 
valley slipping behind the peak on the ring below. For the 
Multilink 8, an in-phase three connector stent with aligned 
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Figure 3 Panels A–D show a 12 mm exposed Biomatrix stent prior to symmetrical loading (A), at 4 mm (B) and following 
7 mm compression in orthogonal views (C,D). Panels E–G show a 7 mm exposed Multilink ML8 (Xience V) stent exposed 7 mm 
prior to symmetrical loading (E) and at 2 mm (F) and following 4 mm compression (G). Panels H–J show an Omega (Element) 
stent exposed 4 mm prior to symmetrical loading (H), at 1.5 mm (I) and following 2.5 mm compression (J). Panels K–N show a 
12 mm exposed Integrity (Resolute) stent prior to point loading (K), at 4 mm (L) and following 7 mm compression in orthogonal 
anteroposterior (M) and lateral (N) views. Panels O–Q show a 7 mm exposed Multilink ML8 (Xience V) stent exposed 7 mm prior 
to point loading (O) and at 2 mm (P) and following 4 mm compression (Q). Panels R–T show an Omega (Element) stent exposed 
4 mm prior to point loading (R), at 1.5 mm (S) and following 2.5 mm compression (T). The appearances of the stents following 
point loading closely resemble cases of longitudinal stent deformation .
Interventional cardiology
connectors, ring-to-ring contact occurred only very late. 
Online supplementary figure S4 shows a comparison 
between two stents with differing connector alignments. 
The Multilink 8, with diagonally aligned connectors, was 
compared with the Omega, with non-aligned connectors. 
The Multilink 8 resisted compression to a higher force 
compared with the Omega.
dIsCussIOn
The Biomatrix stent was the strongest and the Omega 
platform the weakest in terms of LSD at all exposure 
lengths tested. At short exposure lengths (4 mm), the 
Promus Premier was as strong as Multilink and Integrity 
but it was weaker at longer exposed lengths (12 mm).
Ormiston et al have previously attributed the difference 
between stents on mandril testing to connector number 
as one of the factors responsible.5 Recently, a second 
study by Ormiston et al showed that at 5 mm exposed 
length the 3 mm Biomatrix Flex was the strongest stent; 
Omega the weakest stent; and Promus Premier, Integ-
rity, Multilink and Vision had intermediate longitudinal 
rigidity.7 However, the Promus Premier has the most 
connectors between the proximal three hoops compared 
with the other stents studied, implying that these differ-
ences are likely multifactorial rather than solely related to 
connector numbers.
Prabhu et al explained the differences between the 
Element stent and the other platforms, prior to the advent 
of the Premier stent, in terms of the angle and positioning 
of the connectors, with the offset peak-to-peak connector 
of the Element stent allowing nesting of rings.4 In-phase 
rings neatly nest into each other without contacting each 
other until substantial shortening has occurred, whereas 
out-of-phase rings contact each other very early due to 
contact between the valley of a ring above and the peak 
of a ring below (online supplementary figure S3). This 
difference is seen when the in-phase Multilink, Omega 
and Premier designs are compared with the out-of-phase 
Integrity and Biomatrix designs. Examination of the 
force–displacement graphs showed that each contact 
added to the force required to compress these stents and 
that ring-to-ring contact was an important mechanism of 
longitudinal rigidity for out-of-phase designs. Contrary to 
Prabhu, our findings suggest that it is not distortion in 
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the Element connector itself but rather the in-phase ring 
orientation and the non-aligned two-connector design 
that causes nesting of the rings (rather than the part of 
the crown (peak or valley) where the connectors joined).
Connector number is well known to influence longi-
tudinal rigidity, with four connectors stronger than 
two connectors.5 We observed the compound effect 
of connector number and connector alignment by 
comparing the in-phase thin strut Multilink stent and 
Omega stents. Both are in-phase designs with two connec-
tors in the Omega which are non-aligned and three 
connectors in the Multilink which are aligned. The Multi-
link stent depends almost entirely on its aligned connec-
tors to resist longitudinal compression with ring-to-ring 
contact occurring only very late (online supplementary 
figure S3). As the connectors are aligned, the connector 
from one ring pushes on the connector from the ring 
below allowing rigidity to be maintained throughout 
the stent (online supplementary figure S4). In contrast, 
the Omega stent structure allows the portion of the ring 
attached to a connector from the ring above to directly 
approach the ring below, and the in-phase design allows 
each ring to nest into each other, offering little resistance 
to compression (online supplementary figure S4).
It is known that LSD affects predominantly the prox-
imal edge. The Promus Premier stent has a hetero-
geneous connector distribution. This feature aims to 
increase its resistance to LSD, while retaining the high 
conformability, deliverability and fracture resistance 
of the Element design by not having extra connectors 
throughout.7 However, our results suggest that although 
this design modification makes the stent more resistant to 
compression at shorter exposed length, at longer exposed 
lengths we found it weaker than all the other platforms, 
apart from the Omega/Element platform. Clinically, it is 
likely the Promus Premier stent will be very resistant to 
LSD at short exposed lengths (eg, ostial stenting of the 
left anterior descending artery with minimal protrusion 
into the left main stem), but more susceptible than other 
platforms at long exposed lengths (such as bifurcation 
stenting or with a long stent in a tapered vessel prior to 
postdilation). Interestingly, the pattern of LSD is also 
likely to be different, with deformation located 3 mm into 
the stent, due to force transmission from the rigid prox-
imal three rings that are resistant to deformation due to 
the extra connectors as is evidenced from the still photo 
images (figure 2). This may positively affect re-entry into 
a deformed Premier stent.
Strut thickness is also a relevant factor. The Biomatrix 
stent has non-aligned connectors, but is the strongest 
stent. Its strength comes in part from its three connec-
tors and out-of-phase rings in a similar way to the Multi-
link and Integrity stents, respectively, but is stronger than 
both, because of its greater strut thickness.
LSD is an infrequent but important complication of 
coronary intervention. However, reducing the suscepti-
bility to LSD is only one of several factors which influ-
ence stent design, including more important factors such 
as radial strength, conformability and deliverability. As 
such, designing a stent involves a compromise between 
these various factors. The findings in this paper focus on 
the multiple factors that might influence stent suscepti-
bility to LSD. Based on our findings and correlating these 
with the structure of the stent platforms (table 1), we 
propose four factors: ring alignment (in or out of phase), 
connector number and heterogeneity in connector 
number within stent, strut rigidity/thickness and 
connector alignment. However, these are only postu-
lations and not definitive conclusions, considering the 
limited number of stents tested. Furthermore, anticipated 
length of exposure of a stent that could be susceptible to 
LSD could have a bearing on the choice of stent, tailored 
to the procedure. Newer, more contemporary stents in 
the market include the Synergy (Boston Scientific) stent. 
The Synergy stent platform is based on modifications of 
the Promus Element platform to address, among other 
factors, longitudinal strength.9 The design has incorpo-
rated a number of the factors discussed above, including 
additional proximal and distal connectors, altered angle 
of alignment of the connectors, altered radius of the ring 
peaks and thinner struts, in an attempt to increase longi-
tudinal strength and deliverability. It will be interesting to 
see what impact this has on LSD incidence with this stent 
in clinical practice.
limitations
The current study is limited in terms of number of stent 
platforms tested and the conclusions drawn are only 
based on the stent platforms studied. Thus, the results can 
be considered to be at most hypothesis generating. The 
deformation secondary to point loading in our model 
involved two components, shortening along the longitu-
dinal axis of the stent and tilting/bending. The degree of 
tilt (angle, α) was less for the Element and Premier stents, 
meaning that deformation was predominantly shortening 
rather than tilting. If the gap between the stent and the 
outer tube had been less than the 0.75 mm in our coro-
nary model, tilting would have been more restricted and 
a greater difference between these stents and the other 
platforms may have been observed. Clinically, the gap 
between a stent and the vessel wall prior to postdilation 
is likely to be less than 0.75 mm at midvessel locations, 
but could be at least 0.75 mm ostially and in the left main 
stem. The larger 1.75 mm gap in the symmetrical testing 
model allowed considerable lateral movement, and again 
greater differences between the platforms may have been 
observed if this had been reduced.
COnClusIOn
The findings of this paper are hypothesis generating 
and based on a comparative study on five stent platforms 
only. We have, for the first time, used a clinically relevant 
bench model of compression testing at three different 
exposure lengths. The study suggests several observa-
tions that might be related to the susceptibility of stent 
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platforms to LSD. More importantly, we have highlighted 
our lack of clear understanding of the exact factors which 
increase susceptibility to LSD. Furthermore, stent design 
is complex and LSD is only one of several factors, some 
more important than LSD, that influence stent design. 
Until the time when stents will be resistant to LSD, no 
alternative to a judicious interventional technique exists. 
The advent of a clinically relevant model, as used in 
this study, and the multifactorial susceptibility to LSD 
suggested, certainly warrant further studies using a larger 
range of more contemporary platforms to clearly eluci-
date the factors behind the susceptibility to LSD.
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